Polaryx Therapeutics selects CRO for SOTERIA Phase 2 trial
Reuters
Feb 17
Polaryx <a href="https://laohu8.com/S/LENZ">Therapeutics</a> selects CRO for SOTERIA Phase 2 trial
Polaryx Therapeutics Inc. announced the selection of a contract research organization (CRO) for its SOTERIA Phase 2 basket trial. The trial will evaluate the safety, tolerability, and clinical activity of the company’s lead candidate, PLX-200, across four lysosomal storage disorders. The trial is expected to begin in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655595-en) on February 17, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.